

# A rare gain of function *HCN4* gene mutation is responsible for inappropriate sinus tachycardia in a Spanish family

Anabel Cámara-Checa,<sup>1,2\*</sup> Francesca Perin,<sup>3,4\*</sup> Marcos Rubio-Alarcón,<sup>1,2</sup> María Dago,<sup>1,2</sup> Teresa Crespo-García,<sup>1,2</sup> Josu Rapún,<sup>1,2</sup> María Marín,<sup>2</sup> Jorge Cebrián,<sup>1,2</sup> Francisco Bermúdez-Jiménez,<sup>3,4,5</sup> Lorenzo Monserrat,<sup>2,6</sup> Juan Tamargo,<sup>1</sup> Ricardo Caballero,<sup>1,2#</sup> Juan Jiménez-Jáimez,<sup>3,4</sup> Eva Delpón.<sup>1,2#</sup>

<sup>1</sup>Department of Pharmacology and Toxicology. School of Medicine. Universidad Complutense de Madrid. Instituto de Investigación Gregorio Marañón. 28040-Madrid, Spain.

<sup>2</sup>CIBERCV. Instituto de Salud Carlos III. Spain.

<sup>3</sup>Department of Pediatric Cardiology. Virgen de las Nieves University Hospital. 18014-Granada, Spain.

<sup>4</sup>Instituto de Investigación Biosanitaria de Granada IBS. 18014-Granada, Spain

<sup>5</sup>Centro Nacional de Investigaciones Cardiovasculares (CNIC). 28029-Madrid, Spain

<sup>6</sup>Health in Code SL. 15008-A Coruña, Spain.

#Co-senior authors

\*Both authors contributed equally

**Short title:** p.V240M HCN4 and inappropriate sinus tachycardia

## Corresponding author:

Ricardo Caballero

Department of Pharmacology and Toxicology.

School of Medicine

Universidad Complutense de Madrid

Ramón y Cajal Square

28040-Madrid. SPAIN

rcaballero@ucm.es

33 **ABSTRACT**

34 **Background.** In a family with inappropriate sinus tachycardia (IST) we identified a novel  
35 mutation (p.V240M) of the hyperpolarization-activated cyclic nucleotide-gated type 4 (HCN4)  
36 channel, which contributes to the pacemaker current ( $I_f$ ) in human sinoatrial node cells. Here we  
37 clinically study the family and functionally analyze the p.V240M variant.

38 **Methods.** Macroscopic ( $I_{HCN4}$ ) and single-channel currents were recorded using patch-clamp in  
39 cells expressing human native (WT) and/or p.V240M HCN4 channels.

40 **Results.** All p.V240M mutation carriers exhibited IST (mean heart rate 113[7] bpm, n=9), that in  
41 adults, was accompanied by cardiomyopathy.  $I_{HCN4}$  generated by p.V240M channels either alone  
42 or in combination with WT was significantly greater than that generated by WT channels. The  
43 variant, which lies in the N-terminal HCN domain, increased single-channel conductance and  
44 opening frequency and probability of HCN4 channels. Conversely, it did not modify channel  
45 sensitivity for cAMP and ivabradine or the level of expression at the membrane. Treatment with  
46 ivabradine based on functional data reversed the IST and the cardiomyopathy of the carriers.

47 **Conclusions.** The p.V240M gain-of-function variant increases  $I_f$  during diastole, which explains  
48 the IST of the carriers. The results demonstrate the importance of the unique HCN domain in  
49 HCN4 which stabilizes the channels in the closed state.

50

51 **Funding.** Ministerio de Ciencia e Innovación (PID2020-118694RB-I00); Comunidad Autónoma de  
52 Madrid (P2022/BMD-7229), European Structural and Investment Funds); and Instituto de Salud  
53 Carlos III (CIBERCV; CB16/11/00303).

## 54 INTRODUCTION

55 Inappropriate sinus tachycardia (IST) is a clinical syndrome with an estimated prevalence of  
56 around 1% (more frequent in young women) and a significant impact on the quality of life of the  
57 affected individuals (Baruscotti et al., 2016; Olshansky and Sullivan, 2019). IST is defined by a  
58 sinus heart rate (HR) inexplicably higher than 100 beats per min (bpm) at rest or higher than 90  
59 bpm on average over 24 hours. The pathophysiology of IST is still not fully understood as the  
60 processes involved in pacemaking and its modulation are extremely complex (Baruscotti et al.,  
61 2016; Olshansky and Sullivan, 2019). Any participating mechanisms can affect the HR and result  
62 in this syndrome, including an intrinsic increase in sinoatrial node automaticity (Baruscotti et al.,  
63 2016), excess sympathetic tone and reduced cardiovagal tone (Nwazue et al., 2014), and  
64 circulating anti-beta-adrenergic receptor antibodies (Chiale et al., 2006), among others.

65 The hyperpolarization-activated cyclic nucleotide-gated (HCN) channel family comprises 4  
66 members (HCN1-4) and have the peculiarity that they are activated by hyperpolarization rather  
67 than depolarization (Biel et al., 2009). These channels are expressed in the heart and in the  
68 central and peripheral nervous systems and exhibit a unique ion selectivity since they allow the  
69 passage of a depolarizing mixed Na<sup>+</sup> and K<sup>+</sup> current (Biel et al., 2009). In the heart, the current is  
70 known as pacemaker or funny current (I<sub>f</sub>) (because of its quite unusual biophysical profile) and  
71 has a key role in controlling the rhythmic activity in sinoatrial node cells (Biel et al., 2009;  
72 DiFrancesco, 2010; Hennis et al., 2022; Rivolta et al., 2020). Neuronal current is generally  
73 designated as hyperpolarization-activated current or I<sub>h</sub> and contributes to controlling neuronal  
74 excitability. HCN channels contain a cyclic nucleotide-binding domain (CNBD) in the carboxyl  
75 terminus connected to the pore-forming S6 transmembrane segment via the C-linker (Lee and  
76 MacKinnon, 2017). cAMP or cGMP binding to the CNBD induces a rightward shift of the voltage  
77 dependence of HCN4 channel activation (DiFrancesco and Tortora, 1991; Wainger et al., 2001),  
78 thus increasing the current. Furthermore, all HCN channel isoforms contain an N-terminal  
79 domain (HCND) that, in HCN1 and HCN2 has been demonstrated to stabilize the closed pore in  
80 the setting of a depolarized voltage sensor and that physically interacts with the CNBD and the  
81 voltage-sensor domain (VSD) (Lee and MacKinnon, 2017; Porro et al., 2019). HCN family  
82 members differ in their sensitivity to cAMP, opening kinetics, and preferential tissue distribution  
83 (Biel et al., 2009). It is generally accepted that in all mammalian species studied so far, HCN4 was  
84 found to be the main HCN channel isoform in the sinoatrial node although HCN1 and HCN2  
85 isoforms are also present (Baruscotti et al., 2016, 2005; Shi et al., 1999). However, there are data


86 suggesting that HCN1 is the predominant isoform expressed in the human sinoatrial node (Li et  
87 al., 2021, 2015).

88 In a large Spanish family with IST, we identified a novel heterozygous mutation (p.V240M) within  
89 the HCND of HCN4 channels. Understanding the pathophysiology of IST is crucial to find a  
90 treatment for this debilitating condition. For its part, the gating properties of HCN4 channels  
91 and their role in cardiac pacemaking are currently not fully understood. Thus, we decided to  
92 clinically study all family members and functionally analyze the p.V240M HCN4 mutation  
93 through biochemical and electrophysiological approaches even at the single-channel level. Our  
94 results demonstrated that p.V240M is the first naturally occurring HCND gain-of-function  
95 mutation causing an increased inward current flow during diastole accounting for the faster-  
96 than-normal heart rate of all carriers, that was reversed with treatment with ivabradine, a  
97 selective HCN channel blocker (Baruscotti et al., 2005). Moreover, at the molecular level our  
98 findings demonstrate the critical importance of the HCND in the gating o Our results strengthen  
99 the importance of genetic and functional studies in families carrying mutations with uncertain  
100 significance since they allow the implementation of a personalized treatment f HCN4 channels.  
101 and help to the understanding of the mechanisms controlling human cardiac  
102 electrophysiological properties.

## 103 RESULTS

### 104 Clinical and genetic characteristics of the patients

105 The proband (III.3 in Figure 1A) is a female in her 30's (31-35), with a mean 24-h HR of 106[17]  
106 bpm (Table 1 and Figure 1B). After a thorough evaluation, no reversible causes of sinus  
107 tachycardia were found (i.e., hyperthyroidism, anemia, diabetes, orthostatic hypotension,  
108 infections, and drug abuse), thus establishing the diagnosis of IST. The echocardiogram and  
109 cardiac magnetic resonance (CMR) showed mild systolic dysfunction [left ventricular ejection  
110 fraction (LVEF)=43%], and no gadolinium enhancement. No signs of left ventricular  
111 noncompaction or hypertrabeculation were found. Her resting HR and electrocardiographic  
112 (ECG, in at least three different recordings) and cardiac structural parameters are described in  
113 Table 2. Clinical evaluation of her relatives revealed that her father, two siblings, two sons, and  
114 three nephews also fulfilled diagnostic criteria of IST, with a mean resting HR of 113[7] bpm  
115 (Table 1 and Figure 1).



116


117 **Figure 1.** A family with inappropriate sinus tachycardia. (A) Pedigree of the IST proband's family. The arrow indicates  
118 the proband (III.3), circles and squares represent females and males, respectively. (B) Twelve-lead ECGs of II.1, III.3,  
119 and IV.9 family members (paper speed 25 mm/s).

120

121 Six more relatives were also clinically studied and none of them was diagnosed with IST (Table  
122 1). No significant electrocardiographic or structural findings were detected in any of the IST  
123 patients (Table 2). However, all adults with IST (5 out of 9) had reduced LVEF without gadolinium  
124 enhancement, whereas children did not have cardiac dysfunction (Table 1 and Figure 1). As  
125 expected, the HR of children was higher than that of adults (mean 24-h HR: 115.2[5.3] vs.  
126 102.7[2.1] bpm,  $P < 0.05$ ,  $n \geq 4$ ). Patients IV.4 and IV.8 were diagnosed with fetal tachycardia with

127 HR at 160-170 bpm at birth (>98 percentile). The proband's aunt (II.3) had died after heart  
128 transplant due to a congenital heart defect.

129 These data suggested that in this family there was a genetic component responsible for the IST.  
130 Next-generation sequencing (Table Supplement File 1) of the proband identified the pathogenic  
131 (according to the guidelines for the interpretation of variants, Table 3 and Methods)  
132 heterozygous 15,73659894,C,T (NM\_005477.3:c.718G>A) variant in *HCN4* gene encoding  
133 p.V240M HCN4 (Figure 2A). The mutated residue is highly conserved among different species  
134 and lays in the HCND of the protein (Figure 2 B-D).



135

136 **Figure 2.** The V240 residue is highly conserved and lays in the HCND of the protein. (A) DNA sequence chromatogram  
137 depicting the heterozygous *HCN4* variation (15,73659894,C,T; c.718G>A) in the proband. (B) Schematic diagram of  
138 human HCN4 channel highlighting some key domains and the approximate location of the p.V240M variant. (C and D)  
139 Sequence alignment of the region surrounding the V240 residue in HCN4 of several species (C) or in the four channels  
140 of the HCN family (D). The boxes in panels C and D highlight the conservation of this residue.


141

142 The p.V240M variant has been previously annotated with an allele frequency of 0.000003982  
143 (<https://gnomad.broadinstitute.org>, accession date: 11/21/2022) since it was detected on a  
144 single allele in a south Asian subject. Cascade screening demonstrated the genotype-phenotype  
145 co-segregation of the *HCN4* variant (Figure 1A). All carriers except II.1, who refused any

146 treatment, were initially treated with ivabradine alone (7.5 mg BID for adults and 5 mg BID for  
147 the youngest carrier) with a significant response in terms of mean 24-h HR decrease (94[7] vs.  
148 109[7.9],  $P < 0.05$ ) and improvement in symptoms and quality of life (Table 1). Three adult  
149 patients had their ivabradine dose reduced (5 mg BID) since they experienced mild weakness  
150 and dizziness, which are frequently associated with the use of this drug. Bisoprolol (5 mg BID)  
151 was added to them to achieve a better HR control (from 91[1.5] before to 84[5] after bisoprolol).

## 152 Macroscopic current analysis

153 To test whether the p.V240M HCN4 mutation underlies the IST in this family we functionally  
154 analyzed this variant. Figure 3A shows macroscopic HCN4 current ( $I_{HCN4}$ ) traces generated in  
155 three different CHO cells transfected with WT, p.V240M, and the combination of WT and  
156 p.V240M HCN4 channels (0.5:0.5 ratio).  $I_{HCN4}$  comprises two components (inset in Figure 3A):  
157 the minor instantaneous ( $I_{INS}$ ) and the major slowly developing steady-state current ( $I_{SS}$ ), whose  
158 amplitude progressively increased at more negative potentials (Biel et al., 2009; Mistrík et al.,  
159 2006).



160

161 **Figure 3.** Macroscopic currents generated by WT and p.V240M HCN4 channels. (A and B)  $I_{HCN4}$  traces (A) and  
162 density–voltage relationships (B) generated in CHO cells transiently expressing WT, p.V240M, and WT+p.V240M  
163 HCN4 channels by applying the protocol depicted at the top. The inset in A shows the minor instantaneous ( $I_{INS}$ ) and  
164 the major slowly developing steady-state HCN4 current ( $I_{SS}$ ) and the inset in B, shows the data at potentials positive to


165 -90 mV in an expanded scale. (C) Normalized tail current densities generated by WT, p.V240M, and WT+p.V240M  
166 channels by applying 1-second pulses to -140 mV were plotted against the membrane potential of the test pulse.  
167 Continuous lines represent the Boltzmann fit to the data. (D) Fully activated  $I_{HCN4}$  density–voltage relationships  
168 generated by WT, p.V240M, and WT+p.V240M channels. Continuous lines represent the linear regression to the data.  
169 In B-D, each point represents the mean $\pm$ SEM of  $\geq 15$  experiments/cells (biological replicates) from  $\geq 3$  dishes. In B,  
170 \* $P < 0.05$  vs. HCN4 WT. # $P < 0.05$  vs. HCN4 WT and  $P < 0.05$  vs. p.V240M. Two-way ANOVA and Multiple t-test.

171 **Figure 3**-source data 1 of panels B, C, and D.

172

173  $I_{HCN4}$  generated by p.V240M channels (measured at the end of the pulses) was significantly  
174 greater than that generated by WT channels (Figure 3A and 3B) in a wide range of membrane  
175 potentials that includes physiological membrane potentials ( $-1.2 \pm 0.2$  vs.  $-8.6 \pm 2.6$  pA/pF at -60  
176 mV;  $P < 0.05$ ,  $n = 19$ ) (Table 4). Interestingly, densities of  $I_{HCN4}$  generated by the cotransfection of  
177 WT and p.V240M channels were also significantly greater than those of WT channels (Figure 3A  
178 and 3B and Table 4). Figure 3C shows that the p.V240M variant either alone or in combination  
179 with WT channels, significantly and markedly shifted the midpoint ( $V_h$ ) of the activation curve  
180 to more depolarized membrane potentials as assessed by Boltzmann fits (Table 4).

181 Activation time constant ( $\tau_{act}$ ) at -160 mV averaged  $509 \pm 40$ ,  $354 \pm 42$ , and  $438 \pm 40$  ms for  $I_{HCN4}$   
182 generated by WT, p.V240M, or WT+p.V240M HCN4 channels, respectively (Figure 4). Thus, the  
183 p.V240M mutation either alone or in combination with WT channels, significantly accelerated  
184 the activation of  $I_{HCN4}$  ( $P = 0.026$ ,  $n \geq 17$ ).



185



186 **Figure 4.** p.V240M HCN4 modifies the time dependence of  $I_{HCN4}$  activation. **(A)** Mean time constant of activation ( $\tau_{act}$ )  
187 yielded by the fit of a monoexponential function to the activating phase of HCN4 current ( $I_{HCN4}$ ) traces elicited by pulses  
188 to -160 mV in cells expressing WT, p.V240M or WT+p.V240M channels. Each bar represents the mean $\pm$ SEM of n  
189 experiments and each dot represents one experiment. **(B)**  $I_{HCN4}$  traces recorded by applying the protocol shown at the  
190 top to measure deactivation kinetics consisting of two 3-s pulses from -40 to -120 mV that were applied at increasing  
191 coupling intervals (1-6 s). For each coupling interval, we measured the instantaneous current ( $\Delta I_{INS}$ ) and the steady-  
192 state current ( $I_{SS}$ ) elicited at the beginning and at the end, respectively, of the second pulse to -120 mV. **(C)** Mean  
193  $\Delta I_{INS}/I_{SS}$  measured at each coupling interval for  $I_{HCN4}$  recorded in cells expressing WT, p.V240M or WT+p.V240M  
194 channels. A monoexponential function was fitted to the data to obtain the time constant of deactivation ( $\tau_{deact}$ ). Each  
195 point was the mean $\pm$ SEM of  $\geq 7$  experiments (biological replicates). In A and C, \* $P < 0.05$  vs WT. Two-way ANOVA and  
196 multiple t-test. An F-test was performed to determine the statistical significance of the differences between activation  
197 time constants obtained in E.

198 **Figure 4-source data 1** of panels A and C.


199

200 Channel deactivation properties were analyzed using a double pulse protocol (Schweizer et al.,  
201 2010). Figure 4C shows that deactivation of p.V240M channels alone, but not in combination  
202 with WT, was significantly slower than that of WT channels ( $P < 0.05$ ,  $n \geq 7$ ) and, as a consequence,  
203 the ratio of p.V240M channels that remained activated is greater for all the interpulse intervals  
204 (Table 4).

205

#### 206 **Effects of cAMP on p.V240M HCN4 channels**

207 Interestingly, effects produced by the p.V240M variant are quite similar to those produced by  
208 cAMP (DiFrancesco and Tortora, 1991) and thus, we hypothesized that the mutation increases  
209  $I_{HCN4}$  by augmenting HCN4 channel affinity for cAMP. Since HCN4 activation is not affected by  
210 cAMP when channels are expressed in CHO cells (Peters et al., 2020), we tested our hypothesis  
211 in HEK293 cells that were exposed to a saturating cAMP concentration (10  $\mu$ M) in the whole-cell  
212 pipette solution.



213

214 **Figure 5.** Effects of cAMP on the voltage dependence of  $I_{HCN4}$  activation. (A and B) Voltage dependence of  $I_{HCN4}$   
215 generated by WT (A) and p.V240M (B) channels expressed in HEK293 cells in the presence or absence of 10  $\mu$ M  
216 cAMP. Tail current densities generated by applying 1-s pulses to -140 mV were normalized and plotted against the  
217 membrane potential of the test pulse. Continuous lines represent the Boltzmann fit to the data. Each point represents  
218 the mean $\pm$ SEM of  $\geq 6$  experiments/cells (biological replicates) from  $\geq 3$  dishes.

219 **Figure 5-source data 1** of panels A and B.


220

221 As expected, cAMP significantly shifted the activation curve of WT HCN4 channels toward  
222 depolarizing potentials (Figure 5A). In HEK293 cells the  $V_h$  of p.V240M HCN4 channel activation  
223 was also significantly more depolarized than that of WT channels ( $-111.3 \pm 3.8$  mV,  $n \geq 8$ ,  $P < 0.05$ ).  
224 Importantly, voltage-dependent activation of p.V240M channels was significantly shifted in the  
225 presence of cAMP ( $-97.1 \pm 5.2$  mV,  $n \geq 6$ ,  $P < 0.05$ ) (Figure 5B).

226

### 227 **Effects of the p.V240M HCN4 mutation on the membrane expression**

228 To analyze whether an increase of the expression of p.V240M HCN4 channels at the plasma  
229 membrane accounted for the  $I_{HCN4}$  increase, we conducted a cell surface biotinylation assay  
230 (Figure 6) measuring the levels of expression of total HCN4 protein (inputs) and membrane  
231 fraction (biotinylated) by Western blot (WB) (Figure 6A). Figure 6B shows the densitometry of  
232 the relative surface expression of WT and p.V240M HCN4 subunits and demonstrates that there  
233 were not significant differences in the expression of mutated and WT channels ( $P > 0.05$ ,  $n = 5$ ).



234

235 **Figure 6.** Membrane expression of WT and p.V240M HCN4 channels. Representative WB images (A) and  
236 densitometric analyses (B) of biotinylation assays showing the total (input) or surface (membrane) expression of HCN4  
237 in cells expressing WT or p.V240M channels. The cytosolic protein ezrin was used as a negative control. In B, each  
238 dot represents 1 experiment and each bar the mean±SEM of n experiments (biological replicates). Unpaired Student  
239 t-test.

240 **Figure 6**-source data 1 of panel A.


241 **Figure 6**-source data 2 of panel B.

242

243

#### 244 **Single-channel properties of p.V240M HCN4 channels**

245 Figure 7 shows representative single-channel traces recorded in CHO cells at -90 mV in the  
246 absence (control, top panels) or the presence (bottom panels) of ivabradine (5 μM), a selective  
247 I<sub>f</sub> inhibitor (Baruscotti et al., 2005), using the cell-attached configuration.



248


249 **Figure 7.** Single-channel recordings generated by WT and p.V240M HCN4 channels.

250 Single channel recordings obtained by applying 3-s pulses from 0 to -90 mV in cells expressing or not (A) WT (B) or  
251 p.V240M (C) HCN4 channels in the absence and presence (D-F) of ivabradine 5 μM.

252

253 In all experiments we confirmed that ivabradine perfusion completely inhibited the unitary  
254 HCN4 current ( $i_{\text{HCN4}}$ ). Importantly, the p.V240M mutation did not modify the HCN4 channel  
255 sensitivity to ivabradine (Figure 8). No single-channel recordings were obtained in non-  
256 transfected cells since they do not express endogenous HCN4 channels (Figure 7A and 7D).

257



258


259 **Figure 8.** p.V240M does not modify HCN4 channel sensitivity to ivabradine. Concentration-response curves for  
260 ivabradine-induced inhibition of the  $I_{\text{HCN4}}$  recorded at -140 mV in cells expressing WT or p.V240M HCN4 channels.  
261 Solid lines represent the fit of a Hill equation to the data; the nH was fixed to unity, and bottom and top values to 0 and

262 100%, respectively. Each point was the mean±SEM of at least 3 experiments/cells (biological replicates). Statistical  
 263 comparison between both curves was analyzed by an F-test (P=0.51).

264 **Figure 8**-source data 1.

265

266  $i_{HCN4}$  generated by WT channels (Figure 7B) was characterized by spontaneous openings followed  
 267 by periods of channel closure yielding mean  $f_o$  and  $P_o$  values of  $5.2\pm 1.1$  Hz and  $0.11\pm 0.02$  (n=5),  
 268 respectively (Figure 9A and 9B and Table 4).



269

270 **Figure 9.** Gating properties of WT and p.V240M HCN4 channels. Mean  $f_o$  (A),  $P_o$  (B) and open time (C) for  $i_{HCN4}$   
 271 recorded in cells expressing WT or p.V240M HCN4 channels. (D)  $i_{HCN4}$  amplitude generated by WT and p.V240M  
 272 channels after applying pulses to -90 mV. (E)  $i_{HCN4}$ -voltage relationships generated by WT and p.V240M channels. In  
 273 A-D each dot represents 1 experiment/cell and each bar the mean±SEM of n experiments/cells (biological replicates)  
 274 as indicated in the figure. In E each point represents the mean±SEM of  $\geq 4$  experiments/cells (biological replicates).  
 275 \*P<0.05 vs. WT. Unpaired Student t-test. An F-test was performed to determine the statistical significance of the  
 276 differences between conductance values.


277 **Figure 9**-source data 1 of panels A-E.

278

279 Conversely,  $i_{HCN4}$  generated by p.V240M channels was characterized by openings in bursts  
 280 (Figure 7C). Accordingly, both  $f_o$  and  $P_o$  significantly increased, while the mean open time  
 281 significantly decreased compared to those of WT channels (P<0.05, n $\geq 5$ ) (Figure 9A-9C and Table  
 282 4). Moreover,  $i_{HCN4}$  amplitude generated by p.V240M channels at -90 mV (Figure 9D) and at all  
 283 membrane potentials tested was significantly greater than that of WT channels (Figure 9E,

284  $P < 0.05$ ,  $n = 5$ ). Figure 9E shows that single-channel conductance ( $\gamma$ ) derived from the linear  
285 regression of the current-voltage relationships of p.V240M channels was double than that of WT  
286 channels (Table 4). Importantly,  $\gamma$  here obtained for WT channels ( $16.3 \pm 2.7$  pS) is in agreement  
287 with that previously reported for HCN4 channels (Brandt et al., 2009; Michels et al., 2005).

288 Gating kinetics was characterized by means of dwell-time histograms (Methods). Both close and  
289 open dwell-time histograms were fitted by monoexponential functions (Figure 10) yielding  
290  $\tau_{\text{CLOSED}}$  and  $\tau_{\text{OPEN}}$  of 68.1 and 17.3 ms, respectively for WT channels. The mutation significantly  
291 reduced both the  $\tau_{\text{CLOSED}}$  and the  $\tau_{\text{OPEN}}$  ( $P < 0.05$ ) (Table 4 and Figure 10).



292

293 **Figure 10.** p.V240M modifies single channel gating kinetics. (A-D) Closed- (A and C) and open (B and D) dwell-time  
294 histograms for currents recorded in cells expressing HCN4 WT (A and B) or HCN4 p.V240M (C and D) (bin width= 25  
295 ms). Continuous lines represent the fit of a monoexponential function to the data, which yielded the indicated closed  
296 ( $\tau_{\text{CLOSED}}$ ) and open ( $\tau_{\text{OPEN}}$ ) time constants. Histograms were obtained by pooling data from 5 (WT) and 10 (p.V240M)  
297 experiments (biological replicates). \* $P < 0.05$  vs WT (F-test).

298 **Figure 10-source data 1** of panels A-D.


299

### 300 **Mathematical model of human sinoatrial action potentials**

301 Figure 11A shows human sinoatrial APs obtained when running the Fabbri-Fantini-Wilders-  
302 Severi mathematical model (Fabbri et al., 2017) considering the  $I_f$  generated by WT HCN4  
303 channels. AP characteristics are described in Table 5. Spontaneous firing frequency of the AP  
304 averaged 73.8 bpm and it was almost doubled (146.3 bpm) when APs were modeled considering

305 the  $I_f$  generated by p.V240M channels (Figure 11A). The acceleration of the pacemaker  
306 frequency is consequence of the huge increase in the  $I_f$  density produced by the mutation (Figure  
307 11B). Interestingly,  $I_f$  currents generated when considering the heterozygous presence of  
308 p.V240M channels are also greater than those generated by WT channels and the firing  
309 frequency (108 bpm) is close to that of the carriers of the mutation.

### Mathematical model of the human sinoatrial action potentials



310

311 **Figure 11.** Mathematical model of human sinoatrial node cell action potential. (A and B). APs (A) and  $I_f$  (B) obtained  
312 when running the Fabbri-Fantini-Wilders-Severi model under basal conditions (WT; left), or after introducing the  
313 experimentally measured  $I_{HCN4}$  changes induced by p.V240M alone (center) or together with WT (right).

## 314 DISCUSSION


315 In this study we identified several members of a family diagnosed with IST carrying a novel gain-  
316 of-function *HCN4* variant. The results of our functional analysis demonstrated that p.V240M  
317 variant markedly increases the  $f_o$  and the  $P_o$  and depolarizes the voltage dependence of HCN4  
318 channels activation. Thus, the mutation increases  $I_{HCN4}$  by altering the gating without modifying  
319 the channel sensitivity for cAMP and ivabradine or the membrane expression. All these effects  
320 account for the huge increase of  $I_{HCN4}$ , which, in turn, explains the IST of the affected family  
321 members who were treated with ivabradine, which reversed IST and tachycardia-induced  
322 cardiomyopathy.

323 The p.V240M mutation is, to the best of our knowledge, the second HCN4 gain-of-function  
324 mutation described in the literature. The first one was the p.R524Q HCN4 variant, that increases  
325 the channel affinity for cAMP and was described in an Italian family with symptomatic sinus  
326 tachyarrhythmia (Baruscotti et al., 2017). Conversely, many loss-of-function heterozygous  
327 mutations in the *HCN4* gene have been associated with sinus bradycardia that can be  
328 accompanied, or not, with atrial fibrillation, atrioventricular block, structural diseases such as  
329 noncompaction cardiomyopathy, and even QT prolongation (Alonso-Fernández-Gatta et al.,  
330 2021; Cambon-Viala et al., 2021; Macri et al., 2014; Milanese et al., 2006; Nof et al., 2007; Rivolta  
331 et al., 2020; Schweizer et al., 2010; Ueda et al., 2004; Verkerk and Wilders, 2015). As mentioned,  
332 there has been important controversy regarding the role of HCN4 isoforms in generating human  
333  $I_f$  and in pacemaking of sinoatrial node. There are reports demonstrating that the predominant  
334 HCN isoform at both the protein and RNA levels is HCN1 (Li et al., 2021, 2015). However, only a  
335 few data on the literature suggested the contribution of HCN1 variants to HR. One of them is a  
336 case report (Yu et al., 2021) showing two rare *HCN1* heterozygous variants identified in a young  
337 patient with profound sinus bradycardia. The second report identifies a polymorphic *HCN1*  
338 variant that was associated with HR variability and schizophrenia (Refisch et al., 2021).  
339 Conversely, dysfunctional HCN1 channels seem to play an important role in different forms of  
340 epilepsy and neuropathic pain (DiFrancesco et al., 2019; He et al., 2019). Our results add further  
341 support to the contention that in humans, HCN4 channels critically determine  $I_f$  density in  
342 sinoatrial cells, thus regulating HR.

343 The V240 residue is located in the N-terminus, and variants in this domain are less commonly  
344 described than in the pore and C-terminal regions of HCN4 channels. The HCND is formed by a  
345 stretch of 45 aminoacids directly preceding the S1 transmembrane segment that consists of  
346 three  $\alpha$ -helices (HCNa, HCNb, and HCNC) (Figure 2) (Lee and MacKinnon, 2017). The V240



347 residue is actually located in the HCNc  $\alpha$ -helix. The HCND could act as a sliding crank that  
348 converts the planar rotational movement of the CNBD into a rotational upward displacement of  
349 the VSD mechanically coupling thus, the CNBD and the VSD (Porro et al., 2019; Wang et al.,  
350 2020). HCND normally keeps the VSD in a position, which is unfavorable for channel opening  
351 (Porro et al., 2019). To test the possible molecular mechanism responsible for the gain-of-  
352 function effects of p.V240M we have mutated *in silico* a human HCN4 model (PDB:6GYN, Figure  
353 12).



354

355 **Figure 12.** Molecular modeling of WT and p.V240M HCN4 channels. (A) Ribbon representation of the cryo-EM  
356 structure of human HCN4 (PDB:6GYN). Only two diagonal subunits are shown for clarity. The transmembrane  
357 segments (TM) are gray, the HCND is orange, the C-linker is red, the CNBD is blue, and the distal C helix is green. (B)  
358 Close view of superimposed WT and V240M models (colour coded as in A). Sticks representation shows amino acids  
359 side-chains from WT (cyan) and V240M (purple). V240 and M240 are shown as spheres. (C) Interaction of HCND with  
360 the VSD showing the hydrophobic interactions of F229 with I404 and M407 from TM S4 (VSD) and Y258 from the loop  
361 connecting HCND to TM S1, and polar contacts of K228 and Y409 in WT (red dashed line) or K228 and N227 in V240M  
362 (yellow dashed line). Spheres represent the van der Waals surface occupied by the side chains.

363

364 In HCN4 channels the HCND is anchored to the VSD by means of phenylalanine F229, whose  
365 aromatic side chain is inserted between transmembrane helices S1 and S4 in a hydrophobic  
366 pocket formed by I404 and M407 in S4, and Y258 in S1 (Figure 12B-C). Interestingly, the  
367 introduction of the methionine residue at this position remarkably reduced the energy in the  
368 most stable p.V240M conformation ( $-23.49$  kcal/mol) compared to WT ( $-60.18$  kcal/mol).  
369 Moreover, our molecular modeling demonstrates that the mutation introduces a slight torsion

370 of the aromatic group of F229 and prevents the H-bond between K228 in HCND and Y409 in S4  
371 (Figure 12C). These effects might weaken the interaction between HCND and VSD. Thus, these  
372 results suggest that p.V240M mutation limits the inhibitory action of the HCND on the VSD. The  
373 latter could explain the marked positive displacement ( $\approx 20$  mV) of the activation curve of  
374 p.V240M channels. Indeed, our results are in accordance with those obtained by Porro et al  
375 (Porro et al., 2019) who showed that disrupting the interaction between the HCND and the S4  
376 TM of the VSD produced a depolarizing shift in the voltage dependence of activation.

377 The cAMP-induced movement of the C-linker produced by the binding of cAMP to the CNBD is  
378 transmitted via the HCND to the VSD, lowering the energy barrier for channel opening (Porro et  
379 al., 2019; Wang et al., 2020). The mutants that disrupt the contact between the CNBD and the  
380 HCND eliminate the effect of cAMP on channel activation (Porro et al., 2019; Wang et al., 2020).  
381 Results of the molecular modeling demonstrated that the interaction between CNBD and HCND  
382 is not affected by the p.V240M mutation (Figure 12C). The latter would explain why p.V240M  
383 channels are sensitive to cAMP. Interestingly, our results demonstrated that p.V240M mutation  
384 markedly increases single HCN4 channel conductance, an effect that is beyond the positive shift  
385 of the activation curve. We propose that somewhat the mutation introduces changes in the pore  
386 region that controls the conductance of the channel, even when the channel selectivity is not  
387 affected. In summary, and considering that there are very few reports describing single-channel  
388 currents generated by HCN4 channels (Brandt et al., 2009; Michels et al., 2005), our results  
389 contribute to the understanding of the role of HCND in the distinctive biophysical properties of  
390 these channels.

391 The HCND is also necessary for the folding and trafficking of the channel to the plasma  
392 membrane (Porro et al., 2019; Wang et al., 2020). To the best of our knowledge, the only  
393 naturally occurring HCND mutation described so far is p.P257S which was identified in patients  
394 with early-onset atrial fibrillation (Macri et al., 2014). p.P257S channels present a trafficking  
395 defect being retained at the endoplasmic reticulum (Macri et al., 2014). Conversely, the  
396 p.V240M mutant is properly expressed in the membrane suggesting that p.V240M mutation  
397 does not affect the folding and trafficking of HCN4 subunits.

### 398 **Clinical implications**

399 IST is a relatively common clinical entity producing highly distressing symptoms. In most cases,  
400 it is a sporadic non-familial-disease. Here we describe an autosomal-dominant form of IST with  
401 a striking complete penetrance. The clinical manifestations of the carriers are noteworthy, as  
402 they presented with systolic dysfunction. In fact, IST is barely associated with heart dysfunction

403 and tachycardia-induced cardiomyopathy (Olshansky and Sullivan, 2019; Sheldon et al., 2015a)  
404 although some cases have been already reported (Romeo et al., 2011; Winum et al., 2009). Even  
405 when *HCN4* mutations have been related with noncompaction cardiomyopathy (Alonso-  
406 Fernández-Gatta et al., 2021), no signs of hypertrabeculation were found with CMR imaging or  
407 echocardiography in this family. The fact that ivabradine reversed systolic ventricular  
408 dysfunction suggests that the high HR and the duration of the arrhythmia (present from  
409 childhood but being documented even before birth in 2 patients) could have been the major  
410 contributors to cardiac dysfunction in our patients. Regarding treatment of IST, carriers were  
411 treated with ivabradine, since previous reports demonstrated that it reduced HR and improved  
412 quality of life in patients with IST (Cappato et al., 2012). Interestingly, the HR reduction in our  
413 study with ivabradine alone was  $\approx 14\%$  which is similar to that obtained previously in patients  
414 with IST of an unknown origin (Benezet-Mazuecos et al., 2013; Cappato et al., 2012).  
415 Responsiveness of our patients to ivabradine can be explained considering that sensitivity of  
416 p.V240M channels was identical to that of WT HCN4. These results strengthen the importance  
417 of genetic and functional studies for the design of personalized therapies in patients with  
418 inherited arrhythmogenic syndromes.

419 The degree of activation of  $I_f$  at the end of an AP determines the steepness of phase 4  
420 depolarization; hence, the frequency of AP firing (Verkerk and Wilders, 2015). Thus, it seems  
421 reasonable to assume that the gain-of-function p.V240M mutation is responsible for an increase  
422 in sinoatrial node automaticity and the IST of the affected subjects in this family.

## 423 **Conclusions**

424 Our results support the view that individuals carrying the p.V240M mutation present higher than  
425 normal  $I_{HCN4}$ . This variant increases  $I_{HCN4}$  by an unprecedented mechanism that implies the  
426 alteration of the gating without modifying the channel sensitivity for cAMP or the membrane  
427 expression. Therefore, p.V240M is the first naturally occurring gain-of-function HCN4 variant  
428 which explains the faster than normal HR and IST of the carriers. The clinical, genetic and  
429 functional study of the variant led to the establishment of the personalized treatment with  
430 ivabradine for all carriers, contribute to shed light in the understanding of the pathophysiology  
431 of IST and help to the understanding the role of HCN4 channels in the pacemaker activity of  
432 human sinoatrial cells.

## 433 **Methods**

### 434 **Study approval.**

435 All patients signed an informed consent, and the study was approved by the Research Ethics  
436 Committee of Granada (ref: CEIM/CEI/3-19 [12/4/19]). The purpose, methods and ethical aspects  
437 of this specific study were specifically assessed in an ordinary meeting of the Committee.  
438 Moreover, the study conforms to the principles outlined in the Declaration of Helsinki. Genetic  
439 results of the participants were reported following the guidelines proposed by the Working  
440 Group on Reporting Genetic Results in Research Studies (Bookman et al., 2006).

### 441 **Clinical study.**

442 The proband and relatives of a Spanish family with several members diagnosed with IST and left  
443 ventricular (LV) systolic dysfunction were evaluated at the "*Hereditary cardiovascular disease*  
444 *unit*" in the Cardiology Department of the Hospital Universitario Virgen de las Nieves. Trained  
445 personnel performed at least three electrocardiograms ECG at rest to the proband and to all the  
446 family members that gave their written informed consent. Family members either diagnosed or  
447 not with IST underwent a serial 24-hour ECG monitoring (at least two for patients diagnosed  
448 with IST). CMR was performed only to adult family members with IST. Three months after  
449 initiation of medical therapy with ivabradine (7.5 mg BID in adults, 5 mg BID in children) or  
450 ivabradine (5 mg BID) plus bisoprolol (5 mg BID), the 24-h Holter monitoring and echocardiogram  
451 were repeated for every patient, and the findings were compared with those obtained before  
452 treatment. The size of chamber, quantifications, and severity partition cut-offs of LV dysfunction  
453 were measured according to the current guidelines (Sheldon et al., 2015b). IST was defined as  
454 fast sinus rates (>100 bpm at rest or >90 bpm on average over 24 h) not due to underlying  
455 causes. Thus, prior to IST diagnosis, other causes such as hyperthyroidism, anemia, diabetes  
456 mellitus, orthostatic hypotension, infections, and drug abuse, were ruled out. A full pedigree  
457 was obtained collecting information such as cardiac events (sudden cardiac death, heart  
458 transplantation or device implantation), cases of IST, or systolic dysfunction of unknown etiology  
459 and any kind of cardiomyopathy across 4 generations. Echocardiographic, ECG, and imaging  
460 recordings were interpreted by experienced cardiologists, blinded to the genetic and clinical  
461 data of the participants. QT values were corrected using the Bazet's and Fredericia's formulas  
462 in subjects with HR <100 and ≥100 bpm, respectively.

### 463 **Next-generation and Sanger sequencing.**

464 The genetic analysis of the proband was conducted by using a next-generation sequencing panel  
465 including 197 genes (Table Supplement File 1) following procedures previously described  
466 (Caballero et al., 2017; Nieto-Marín et al., 2022). Genomic DNA was extracted using an  
467 automated extraction and purification process by using the QIASymphony SP® kit (Qiagen, Hilde,  
468 Germany) according to the manufacturer's instructions. Library preparation was carried out  
469 using SureSelect Reagent kit (Agilent, Santa Clara, CA, USA) for Illumina's paired-end multiplexed  
470 sequencing method, following the manufacturer's instructions. The enrichment of the regions  
471 of interest was performed by means of a SureSelect (Agilent) probe kit that selectively captures  
472 the coding zones and the flanking intronic areas of the selected genes. After the generation of  
473 clusters, the DNA libraries were sequenced on the Illumina HiSeq 1500 platform. The analysis of  
474 the sequencing data was performed using a proprietary bioinformatics pipeline to obtain a  
475 report of variants noted along with their coverage and corresponding quality parameters. We  
476 excluded variants located in introns (except those in suspected splicing sites) or intergenic  
477 regions. We also removed synonymous variants and non-synonymous variants with occurrences  
478 >1 in our local database. The list of variants identified were evaluated against database  
479 information on previously described variants [Human Gene Mutation Database  
480 (<http://www.hgmd.cf.ac.uk/>), Single Nucleotide Polymorphism (SNP) database  
481 (<http://www.ncbi.nlm.nih.gov/SNP/>), NHLBI GO Exome Sequencing Project  
482 (<http://evs.gs.washington.edu/EVS/>), ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>), or  
483 Genome Aggregation database (<http://gnomad.broadinstitute.org>). Pathogenicity of the  
484 identified variants was established according to the current recommendations of the American  
485 College of Medical Genetics and Genomics and the Association for Molecular Pathology  
486 (Richards et al., 2015). Variant pathogenicity was graded according to its presence in a previously  
487 associated or candidate gene and the *in silico* predicted impact on the protein using widely used  
488 software (PROVEAN, SIFT, Polyphen2, Mutation Taster, and Combined Annotation Dependent  
489 Depletion Score), the degree of conservation of the affected residue measured by multiple  
490 ortholog alignment using Alamut software (<http://www.interactive-biosoftware.com>).

491 A phenotype-genotype segregation study was conducted through cascade screening among  
492 available relatives with Sanger genetic study (Caballero et al., 2017; Nieto-Marín et al., 2022).  
493 PCR products were purified using illustra ExoProStar 1-Step (GE Healthcare Life Sciences,  
494 Chicago, IL, USA) and the analysis was performed by direct sequencing (Health in Code, A  
495 Coruña, Spain). The results were compared with the reference sequence from hg19 by means of  
496 Chromas Lite Software (<http://technelysium.com.au>).

497

498 **Cell culture and transfection.**

499 The study has been conducted in CHO and HEK-293 purchased from American Type Culture  
500 Collection (ATCC, Manassas, VA, USA). They had been authenticated by the supplier as  
501 appropriate. Mycoplasma tests were conducted routinely for both cell lines and showed no  
502 mycoplasma contamination.

503 CHO cells were grown in Ham-F12 medium supplemented with 10% fetal bovine serum, 100  
504 U/ml penicillin, and 100 µg/ml streptomycin (Caballero et al., 2010; Caballero et al., 2017; Pérez-  
505 Hernández et al., 2018; Alonso-Fernández-Gatta et al., 2021; Crespo-García et al., 2023). HEK-  
506 293 cells were cultured in Dulbecco's modified Eagle's (DMEM) medium supplemented with 10%  
507 fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin as previously described  
508 (Caballero et al., 2010; Crespo-García et al., 2023). The cultures were passed every 2–5 days  
509 using a brief trypsin treatment.

510 The p.V240M HCN4 mutation (NP\_005468.1) was introduced by using the QuikChange Site-  
511 Directed Mutagenesis kit (Agilent, Santa Clara, CA, USA) and confirmed by direct DNA  
512 sequencing (Secugen S.L., Madrid, Spain). The sequence of the oligonucleotides used to  
513 introduce the p.V240M substitution was the following: sense 5'  
514 GCAGCCAGAAAGCCaTGGAGCGCAACAG 3'; antisense 5'  
515 CTGTTTCGCGCTCCaTGGCTTTCTGGCTGC 3'. The sequence of the oligonucleotide used for  
516 sequencing was: 5' ACGGACACCTGCATGACTC 3'.

517 For macroscopic current recordings, subconfluent cultures were transiently transfected with  
518 cDNA encoding WT or mutated HCN4 channels (1.6 µg) together with cDNA encoding the CD8  
519 antigen (0.5 µg) by using X-tremeGENE™ HP (Roche Diagnostics, Rotkreuz, Switzerland) in CHO  
520 cells or Lipofectamine 2000 (Thermofisher Scientific, Waltham, MA, USA) in HEK-293 cells, with  
521 manufacturer instructions followed (Caballero et al., 2010; Caballero et al., 2017; Pérez-  
522 Hernández et al., 2018; Alonso-Fernández-Gatta et al., 2021; Crespo-García et al., 2023). In some  
523 experiments, WT and p.V240M HCN4 were cotransfected (WT+p.V240M) at a 0.5:0.5 ratio (0.8  
524 µg each). For single channel recordings, CHO cells were transfected with 0.5 instead of 1.6 µg of  
525 the cDNA encoding mutated or WT HCN4.

526 In all cases, at the point of 48 h after transfection, cells were incubated with polystyrene  
527 microbeads precoated with anti-CD8 antibody (Dynabeads M450, Thermofisher Scientific). Most  
528 of the cells that were beaded also exhibited channel expression. The day of recordings, cells  
529 were removed from the dish by using a cell scraper or by trypsinization, respectively, and the  
530 cell suspension was stored at room temperature and used within 12 h for electrophysiological  
531 experiments.

532 To minimize the influence of the expression variability, each construct was tested in a large  
533 number of cells obtained from at least 3 different cell batches. Moreover, to avoid putative  
534 interferences of culture conditions (passage number, cell density, etc), currents generated by  
535 cells expressing WT, p.V240M and WT+p.V240M channels were always recorded in parallel.

### 536 **Recording techniques.**

#### 537 **Macroscopic current recordings.**

538 A small aliquot of cell suspension was placed in a 0.5 ml chamber mounted on the stage of an  
539 inverted microscope (Nikon TMS; Nikon Co., Tokio, Japan). After settling to the bottom of the  
540 chamber, cells were perfused at  $\approx 1$  mL/min with external solution (see the composition below).  
541 Macroscopic currents were recorded at room temperature (21-23°C) by means of the whole-  
542 cell patch-clamp technique using Axopatch-200B patch clamp amplifiers and pCLAMP software  
543 (Molecular Devices, San José, CA, USA) (Caballero et al., 2010; Caballero et al., 2017; Pérez-  
544 Hernández et al., 2018; Alonso-Fernández-Gatta et al., 2021; Nieto-Marín et al., 2022; Crespo-  
545 García et al., 2023) Recording pipettes were pulled from 1.0 mm o.d. borosilicate capillary tubes  
546 (GD1, Narishige Co., Ltd, Tokio, Japan) using a programmable patch micropipette puller (Model  
547 P-2000 Brown-Flaming, Sutter Instruments Co., Novato, CA, USA) and were heat-polished with  
548 a microforge (Model MF-83, Narishige). Micropipette resistance ranged 3-5 M $\Omega$  when filled with  
549 the internal solution and immersed in the external solution. In all the experiments, series  
550 resistance was compensated manually by using the series resistance compensation unit of the  
551 Axopatch amplifier, and  $\geq 80\%$  compensation was achieved. The remaining access resistance  
552 after compensation and cell capacitance were  $1.7 \pm 0.4$  M $\Omega$  and  $11.9 \pm 0.7$  pF (n=65), respectively.  
553 Therefore, under our experimental conditions no significant voltage errors (<5 mV) due to series  
554 resistance were expected with the micropipettes used. Currents were filtered at half the  
555 sampling frequency and stored on the hard disk of a computer for subsequent analysis. CHO  
556 cells were perfused with an external solution containing (mM): NaCl 110, KCl 30, HEPES 5, MgCl<sub>2</sub>  
557 0.5, CaCl<sub>2</sub> 1.8, and glucose 10; pH= 7.4 with NaOH. Recording pipettes were filled with an internal  
558 solution containing (mM): K-aspartate 80, KCl 42, KH<sub>2</sub>PO<sub>4</sub> 10, MgATP 5, phosphocreatine 3,  
559 HEPES 5 and EGTA 5; pH 7.2 with KOH. The protocol to obtain current-voltage relationships  
560 consisted of 2-s steps that were imposed in 10 mV increments from a holding potential of -40  
561 mV to potentials ranging -160 and 0 mV. Current amplitude was measured at the end of the  
562 pulse and normalized in each experiment to membrane capacitance to obtain current densities.  
563 To determine putative effects on the ion selectivity of HCN4 channels, the reversal potential

564 ( $E_{rev}$ ) was measured at extracellular and intracellular  $K^+$  concentrations of 30 and 142 mM,  
565 respectively. To this end, 3-s pulses to  $-120$  mV followed by 1-s pulse to membrane potentials  
566 ranging  $-50$  to  $+20$  mV were applied. The  $E_{rev}$  was calculated in each experiment from the  
567 intersection of the linear regression to the data with the abscissas axis. To analyze potential  
568 effects on the time course of current activation, a monoexponential function was fitted to the  
569 activation phase of current traces elicited by pulses to  $-160$  mV yielding  $\tau_{act}$  that defines the  
570 process. To measure HCN4 deactivation kinetics, two 3-s pulses from  $-40$  to  $-120$  mV were  
571 applied at increasing coupling intervals (1-6 s) (Mistrík et al., 2006; Schweizer et al., 2010). This  
572 protocol allowed us to calculate, for each coupling interval, the ratio between  $\Delta I_{INS}$  and  $I_{SS}$  elicited  
573 at the beginning and at the end, respectively, of the second pulse to  $-120$  mV. The calculated  
574 ratio was plotted as a function of the coupling interval and a monoexponential function was  
575 fitted to the data to obtain the  $\tau_{deact}$ .

576 The protocol to analyze the voltage dependence of HCN4 channel activation consisted of 2-s  
577 pulses from  $-40$  mV to potentials ranging from  $-160$  to  $0$  mV followed by 1-s pulses to  $-140$  mV  
578 to record the tail currents. The tail current amplitude was normalized to the maximum value  
579 and plotted as a function of the membrane potential of the preceding pulse to construct the  
580 activation curves. A Boltzmann function was fitted to the data to calculate the midpoint ( $V_h$ ) and  
581 the slope ( $k$ ) of the curves. In a subset of experiments, the consequences of the p.V240M variant  
582 on the shift of the voltage-dependent activation produced by of 3',5'-cyclic Adenosine  
583 monophosphate (cAMP) were analyzed in HEK-293 cells. It has been recently described that in  
584 CHO but not in HEK-293 cells, HCN4 channel activation is constitutively shifted to more  
585 depolarized membrane potentials and is no longer affected by cAMP (Peters et al., 2020). In  
586 these experiments, HEK-293 cells cultured and transfected as described above, were perfused  
587 with the same external solution than described for CHO cells (see above), while the internal  
588 solution contained (mM): KCl 130, NaCl 10, MgATP 2, HEPES 5, MgCl<sub>2</sub> 0.5 and EGTA 1; pH 7.2  
589 with KOH. cAMP (Merck, Rahway, NJ, USA) at a saturating concentration ( $10 \mu\text{M}$ ) was added to  
590 the pipette solution.

591 The effects of different concentrations of ivabradine ( $0.1$ - $3 \mu\text{M}$ ) was determined in CHO cells  
592 transfected with WT or p.V240M HCN4 channels by applying trains of activating/deactivating  
593 steps to  $-140$  and  $+5$  mV from a holding potential of  $-35$  mV (Bucchi et al., 2013). The  $I_{HCN4}$   
594 inhibition at  $-140$  mV was used as an index of block ( $f$ ; expressed as percentage of inhibition) to  
595 construct the respective concentration-response curves and a Hill equation ( $f =$   
596  $1/\{1+(IC_{50}/[D])^{n_H}\}$ ) was fitted to the data to obtain the concentration needed to produce the 50%  
597 of the maximum inhibition ( $IC_{50}$ ). In the fit,  $n_H$  was fixed to unity and bottom and top values were  
598 constrained to 0 and 100%, respectively.



599

600 **Single channel recordings.**

601 Single channel currents were recorded in CHO cells at room temperature (21-23°C) using the  
602 cell-attached patch-clamp configuration (Michels et al., 2005; Brandt et al., 2009; Caballero et  
603 al., 2010; Crespo-García et al., 2023). Using this configuration, the intracellular environment is  
604 completely preserved and channel activity can be measured in an intact cell. Cells were  
605 suspended in bath solution containing (mM): KCl 130, NaCl 10, EGTA 5 and HEPES 10; pH 7.4  
606 with KOH. This high-K<sup>+</sup> solution was used to achieve a resting membrane potential of zero. Patch  
607 pipettes were pulled from 1.5 mm o.d. borosilicate capillary tubes (Harvard Apparatus Ltd,  
608 Holliston, MA, USA), coated at the tip with Sylgard (Dow Corning, Midland, MI, USA), and fire-  
609 polished with a microforge (Mod. MF-830. Narishige). When filled with pipette solution  
610 containing (in mM): KCl 70, NaCl 70, MgCl<sub>2</sub> 1, BaCl<sub>2</sub> 2 and HEPES 5; pH 7.4 with KOH, tip  
611 resistances were between 5 and 10 MΩ. The micropipettes were gently lowered onto the cells  
612 to get a gigaohm seal after applying suction. After seal formation, the cells were lifted from the  
613 bottom of the perfusion bath and current recordings were started. Single channel currents were  
614 recorded by applying repetitive 10-s pulses from a holding potential of -35 mV to -90 mV or to  
615 potentials between -120 and +40 mV in 10 mV steps. Current data were sampled at 10 kHz and  
616 filtered at 1 kHz. The apparent number of active channels in a patch was determined by visual  
617 inspection of the current traces and patches with more than one channel were discarded. The  
618 experimental conditions were optimized to reduce the number of active channels on each  
619 recording: e.g., the amount of cDNA used for cell transfection was reduced by ≈70% and the tip  
620 resistance of the pipettes was increased approximately threefold compared to whole-cell  
621 recordings. Under these conditions, only 10% of cells with active channels had more than one  
622 channel. All data analysis was performed by using pCLAMP software and opening events were  
623 captured using the event detection tool of Clampfit 10 (Caballero et al., 2010; Crespo-García et  
624 al., 2023). At the end of each experiment, the HCN channel inhibitor ivabradine (5 μM) (Bucchi  
625 et al., 2006) was added to the external solution to specifically abolish single channel currents  
626 generated by HCN4 channels.

627 Amplitude of unitary currents was determined for each experiment by direct measurements of  
628 fully resolved openings, which allowed the calculation of average values. The opening  
629 probability ( $P_o$ ) was obtained for each experiment by dividing the time that the channel remains  
630 in the open state by the total recording time and the opening frequency ( $f_o$ ) was calculated for  
631 each experiment as the inverse of the closed time between events. The mean open time was

632 calculated for each experiment by dividing the time the channel remains in the open state by  
633 the events. To measure opening and closing kinetics, dwell-time histograms were constructed  
634 by plotting pooled dwell-time data as a function of the number of events per bin that were fitted  
635 by monoexponential functions to calculate  $\tau_{\text{OPEN}}$  and  $\tau_{\text{CLOSED}}$ . Current–voltage relationships were  
636 constructed by plotting the single channel current amplitude as a function of the membrane  
637 potential and conductance ( $\gamma$ ) was calculated from the slope of the fit of a linear function to the  
638 data recorded at potentials between  $-120$  and  $-60$  mV.

639

#### 640 **Biotinylation assay.**

641 A biotinylation assay was conducted in CHO cells using procedures previously described (Crespo-  
642 García et al., 2023). At the point of 48 h after transfection of HCN4 WT or p.V240M, CHO cells  
643 were washed twice with ice cold phosphate-buffer saline (PBS) and biotinylated for 15 min at  
644  $4^{\circ}\text{C}$  using PBS containing 0.5 mg/mL of EZ Link Sulfo-NHS-SS-Biotin (ThermoFisher). Plates were  
645 washed twice with PBS-200 mM glycine (to quench unlinked biotin) and again with PBS. Cells  
646 were collected in RIPA buffer containing 50 mM Tris·HCl (pH=7.5), 150 mM NaCl, 1% Nonidet P-  
647 40, 0.1% SDS, 0.5% sodium deoxycholate, and 1 mM phenylmethylsulfonyl fluoride (PMSF) and  
648 protease inhibitor cocktail (Merck) for protein extraction. Subsequently, the extract (1 mg) was  
649 incubated with Streptavidin Sepharose (50  $\mu\text{l}$ , GE Healthcare) overnight at  $4^{\circ}\text{C}$ . To separate  
650 biotinylated fraction, samples were centrifugated at 3000 rpm for 2 min at  $4^{\circ}\text{C}$ . The fraction of  
651 biotinylated proteins was washed by several centrifugations. Thereafter, HCN4 and ezrin  
652 proteins were detected by Western blot following previously described procedures (Pérez-  
653 Hernández et al., 2018; Nieto-Marín et al., 2022; Crespo-García et al., 2023). Nuclei and cell  
654 debris were removed by centrifugation at 14.000 rpm for 20 min at  $4^{\circ}\text{C}$ . The total protein  
655 amount of the extracts was calculated with the bicinchoninic acid method (Pierce™ BCA Protein  
656 Assay Kit, ThermoFisher). Samples were run on 4-15% Mini-PROTEAN TGX™ stain-free gels (Bio-  
657 Rad, Hercules, CA, USA USA) and, afterwards, protein was transferred to nitrocellulose  
658 membranes. Nonspecific binding sites were blocked with 5% non-fat dried milk in PBS with  
659 Tween-20 (0.05%) for 1 hour at room temperature. Membranes were then incubated with rabbit  
660 polyclonal anti-HCN4 (1:1000; 55224-1-AP, Proteintech, Rosemont, IL, USA) and mouse  
661 monoclonal anti-ezrin (1:400; ab4069, Abcam, Cambridge, UK) primary antibodies overnight at  
662  $4^{\circ}\text{C}$ . All the antibodies had been validated by the manufacturers. After the incubation with the  
663 primary antibodies, samples were incubated for 1 hour with peroxidase-conjugated goat anti-  
664 rabbit (111-035-144) or goat anti-mouse (115-035-003) secondary antibody (1:10000; Jackson

665 Immunoresearch, West Grove, PA, USA). Membranes were washed three times with PBS-Tween  
666 after adding primary and secondary antibodies. Protein expression was detected by  
667 chemiluminescence (SuperSignal™ West Femto Maximum Sensitivity Substrate, ThermoFisher)  
668 and visualized using the Chemidoc MP System and Image Lab 5.2.1. software (Bio-Rad).  
669 Expression of the proteins in the biotinylated (membrane) fraction was normalized to the input  
670 expression.

671

## 672 **Mathematical modeling of human sinoatrial node action potential.**

673 We employed the Fabbri-Fantini-Wilders-Severi model of human sinus node cells (Fabbri et al.,  
674 2017). The model is based on experimental recordings and numerical reconstructions of the  $I_f$   
675 measured in human sinoatrial node cells (Verkerk et al., 2007a, 2007b) and fairly reproduces the  
676 changes in heart rate induced by mutations or drugs affecting the  $I_f$  (Fabbri et al., 2017). We  
677 downloaded the model files available at the CellML model repository  
678 (<http://models.cellml.org/cellml>), as part of the International Union of Physiological Sciences  
679 Physiome Project (Yu et al., 2011). To perform the simulations we used OpenCell software  
680 package that allows reading, modifying, solving, and plotting CellML models ([http://cellml-  
681 opencell.hg.sourceforge.net:8000/hgroot/cellml-opencell/cellml-opencell](http://cellml-opencell.hg.sourceforge.net:8000/hgroot/cellml-opencell/cellml-opencell)). Initially, the model  
682 was run (for 100 s) keeping all parameters at their default values and under these conditions,  
683 the model was stable and reproduced the results obtained in the original description of the  
684 model (Fabbri et al., 2017). The results obtained with these “basal” conditions were considered  
685 to correspond to WT HCN4. Thereafter, the experimentally measured changes produced by  
686 p.V240M HCN4 or WT + p.V240M HCN4 on the conductance, kinetics and voltage dependence  
687 of activation of the macroscopic  $I_f$  were incorporated into the model equations corresponding  
688 to the  $I_f$ . The modified versions of the model were also run for 100 s. In all cases, we plotted  
689 action potential and  $I_f$  traces yielded at the end of the simulation runs and several parameters  
690 were measured including cycle length, beating frequency, diastolic depolarization rate, mean  
691 diastolic potential, action potential amplitude, overshoot, and action potential duration  
692 measured at 20, 50, and 90% of repolarization.

## 693 **Molecular modeling.**

694 To estimate the conformational changes produced by the p.V240M HCN4 mutation a molecular  
695 modeling using the crystallized structure of human HCN4 (PDB: 6GYN) was performed. Model  
696 refinement, in silico mutagenesis, and energy calculation were done with FoldX Suite (version

697 4.0, <https://www.foldxsuite.crg.eu>). For model refinement and minimizing the energy of the  
698 structure, the RepairPDB protocol was used. The Val-to-Met substitution at position 240 of each  
699 monomer of the optimized PDB was performed and the protocol to calculate free energies was  
700 run ten times. Default parameters of the software were used except temperature, pH, ionic  
701 strength and VdW design that were set at 298K, 7, 5 and 0, respectively. When the model  
702 running was completed, the software provided different conformations with different energies  
703 and the conformation of the mutated form with the lowest energy was chosen. The optimized  
704 conformations of WT and p.V240M HCN4 were compared on PyMOL (Molecular Graphics  
705 System, Version 2.0 Schrödinger, LLC; <https://www.pymol.org/2/>) and putative changes in the  
706 aminoacid positions and interactions (Hydrophobic, electrostatic and H-Bonds) with  
707 surrounding residues induced by the presence of the mutation were identified (Caballero et al,  
708 2010).

709

## 710 **Statistical Analyses**

711 Clinical and experimental results are expressed as mean[SD] and mean±SEM, respectively.  
712 Small-sized samples were first analyzed to determine the distribution of the variables  
713 (Normality) using the Shapiro–Wilk and Kilmogorov-Smirnov tests. When these tests  
714 demonstrated a normal distribution, parametric tests were used. Paired or unpaired *t* test,  
715 multiple *t* test, one-way ANOVA followed by Tukey’s test, or two-way ANOVA were used to  
716 assess statistical significance where appropriate. When a statistically significant difference was  
717 determined by these tests, a Pearson correlation was performed to confirm that the observed  
718 differences were not due to random sampling. To make comparisons between fits of pooled or  
719 of concentration-dependent data, an F-test was used. Variance was comparable between  
720 groups throughout the manuscript. A value of  $P < 0.05$  was considered significant. Statistical tests  
721 were conducted using GraphPad Prism 8 ([https://www.graphpad.com/scientific-](https://www.graphpad.com/scientific-software/prism/)  
722 [software/prism/](https://www.graphpad.com/scientific-software/prism/)) or Microsoft Excel. For the different groups of experiments sample size was  
723 chosen empirically according to previous experience in the calculation of experimental  
724 variability. No statistical method was used to predetermine sample size. The cellular  
725 experiments were not blinded due to the nature of the experimental design and platforms but  
726 all the data were analysed in an identical manner for all conditions to eliminate possible operator  
727 bias.

728 **Data availability**

729 All data generated or analyzed during this study are included in the manuscript and supporting  
730 files. CMR and acute and Holter ECGs recordings will be not available since they are incorporated  
731 into the confidential medical record of each participant.

732

733 **Disclosures**

734 The authors declare no conflict of interest

## 735 REFERENCES

- 736 Alonso-Fernández-Gatta M, Gallego-Delgado M, Caballero R, Villacorta E, Díaz-Peláez E, García-  
737 Berrocal B, Crespo-García T, Plata-Izquierdo B, Marcos-Vadillo E, García-Cuenllas L,  
738 Barreiro-Pérez M, Isidoro-García M, Tamargo-Menéndez J, Delpón E, Sánchez PL. 2021. A  
739 rare HCN4 variant with combined sinus bradycardia, left atrial dilatation, and  
740 hypertrabeculation/left ventricular noncompaction phenotype. *Rev Espanola Cardiol Engl*  
741 *Ed* **74**:781–789. doi:10.1016/j.rec.2020.06.019
- 742 Baruscotti M, Bianco E, Bucchi A, DiFrancesco D. 2016. Current understanding of the  
743 pathophysiological mechanisms responsible for inappropriate sinus tachycardia: role of  
744 the If “funny” current. *J Interv Card Electrophysiol Int J Arrhythm Pacing* **46**:19–28.  
745 doi:10.1007/s10840-015-0097-y
- 746 Baruscotti M, Bucchi A, DiFrancesco D. 2005. Physiology and pharmacology of the cardiac  
747 pacemaker (“funny”) current. *Pharmacol Ther* **107**:59–79.  
748 doi:10.1016/j.pharmthera.2005.01.005
- 749 Baruscotti M, Bucchi A, Milanese R, Paina M, Barbuti A, Gnecci-Ruscione T, Bianco E, Vitali-  
750 Serdoz L, Cappato R, DiFrancesco D. 2017. A gain-of-function mutation in the cardiac  
751 pacemaker HCN4 channel increasing cAMP sensitivity is associated with familial  
752 Inappropriate Sinus Tachycardia. *Eur Heart J* **38**:280–288. doi:10.1093/eurheartj/ehv582
- 753 Benezet-Mazuecos J, Rubio JM, Farré J, Quiñones MÁ, Sanchez-Borque P, Macía E. 2013. Long-  
754 term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate  
755 efficacy or inappropriate patients. *Pacing Clin Electrophysiol PACE* **36**:830–836.  
756 doi:10.1111/pace.12118
- 757 Biel M, Wahl-Schott C, Michalakakis S, Zong X. 2009. Hyperpolarization-activated cation  
758 channels: from genes to function. *Physiol Rev* **89**:847–885.  
759 doi:10.1152/physrev.00029.2008
- 760 Bookman EB, Langehorne AA, Eckfeldt JH, Glass KC, Jarvik GP, Klag M, Koski G, Motulsky A,  
761 Wilfond B, Manolio TA, Fabsitz RR, Luepker RV; NHLBI Working Group. 2006. Reporting  
762 genetic results in research studies: summary and recommendations of an NHLBI working  
763 group. *Am J Med Genet A*. 140:1033-1040. doi: 0.1002/ajmg.a.31195.
- 764 Brandt MC, Endres-Becker J, Zagidullin N, Motloch LJ, Er F, Rottlaender D, Michels G, Herzig S,  
765 Hoppe UC. 2009. Effects of KCNE2 on HCN isoforms: distinct modulation of membrane  
766 expression and single channel properties. *Am J Physiol Heart Circ Physiol* **297**:H355–363.  
767 doi:10.1152/ajpheart.00154.2009
- 768 Bucchi A, Tognati A, Milanese R, Baruscotti M, DiFrancesco D. 2006. Properties of ivabradine-  
769 induced block of HCN1 and HCN4 pacemaker channels. *J Physiol* **572**:335–346.  
770 doi:10.1113/jphysiol.2005.100776
- 771 Bucchi A, Baruscotti M, Nardini M, Barbuti A, Micheloni S, Bolognesi M, DiFrancesco D. 2013.  
772 Identification of the molecular site of ivabradine binding to HCN4 channels. *PLoS One*  
773 **8**:e53132. doi:10.1371/journal.pone.0053132
- 774 Caballero R, Dolz-Gaitón P, Gómez R, Amorós I, Barana A, González de la Fuente M, Osuna L,  
775 Duarte J, López-Izquierdo A, Moraleta I, Gálvez E, Sánchez-Chapula JA, Tamargo J, Delpón  
776 E. 2010. Flecainide increases Kir2.1 currents by interacting with cysteine 311, decreasing  
777 the polyamine-induced rectification. *Proc Natl Acad Sci U S A* **107**:15631–15636.  
778 doi:10.1073/pnas.1004021107
- 779 Caballero R, Utrilla RG, Amorós I, Matamoros M, Pérez-Hernández M, Tinaquero D, Alfayate S,  
780 Nieto-Marín P, Guerrero-Serna G, Liu Q-H, Ramos-Mondragón R, Ponce-Balbuena D,  
781 Herron T, Campbell KF, Filgueiras-Rama D, Peinado R, López-Sendón JL, Jalife J, Delpón E,  
782 Tamargo J. 2017. Tbx20 controls the expression of the *KCNH2* gene and of hERG channels.  
783 *Proc Natl Acad Sci U S A* **114**:E416–E425. doi:10.1073/pnas.1612383114

- 784 Cambon-Viala M, Gerard H, Nguyen K, Richard P, Ader F, Prunty J-F, Donal E, Eicher J-C, Huttin  
785 O, Selton-Suty C, Raud-Raynier P, Jondeau G, Mansencal N, Sawka C, Casalta A-C, Michel  
786 N, Donghi V, Martel H, Faivre L, Charron P, Habib G. 2021. Phenotype/Genotype  
787 Relationship in Left Ventricular Noncompaction: Ion Channel Gene Mutations Are  
788 Associated With Preserved Left Ventricular Systolic Function and Biventricular  
789 Noncompaction: Phenotype/Genotype of Noncompaction. *J Card Fail* **27**:677–681.  
790 doi:10.1016/j.cardfail.2021.01.007
- 791 Cappato R, Castelvechio S, Ricci C, Bianco E, Vitali-Serdoz L, Gneccchi-Ruscione T, Pittalis M, De  
792 Ambroggi L, Baruscotti M, Gaeta M, Furlanello F, Di Francesco D, Lupo PP. 2012. Clinical  
793 efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective,  
794 randomized, placebo-controlled, double-blind, crossover evaluation. *J Am Coll Cardiol*  
795 **60**:1323–1329. doi:10.1016/j.jacc.2012.06.031
- 796 Chiale PA, Garro HA, Schmidberg J, Sánchez RA, Acunzo RS, Lago M, Levy G, Levin M. 2006.  
797 Inappropriate sinus tachycardia may be related to an immunologic disorder involving  
798 cardiac beta adrenergic receptors. *Heart Rhythm* **3**:1182–1186.  
799 doi:10.1016/j.hrthm.2006.06.011
- 800 Crespo-García T, Rubio-Alarcón M, Cámara-Checa A, Dago M, Rapún J, Nieto-Marín P, Marín M,  
801 Cebrían J, Tamargo J, Delpón E, Caballero R. 2023. A Cantú syndrome mutation  
802 produces dual effects on KATP channels by disrupting ankyrin B regulation. *J Gen*  
803 *Physiol* **155**:e202112995. doi:10.1085/jgp.202112995
- 804 DiFrancesco D. 2010. The role of the funny current in pacemaker activity. *Circ Res* **106**:434–  
805 446. doi:10.1161/CIRCRESAHA.109.208041
- 806 DiFrancesco D, Tortora P. 1991. Direct activation of cardiac pacemaker channels by  
807 intracellular cyclic AMP. *Nature* **351**:145–147. doi:10.1038/351145a0
- 808 DiFrancesco JC, Castellotti B, Milanesi R, Ragona F, Freri E, Canafoglia L, Franceschetti S,  
809 Ferrarese C, Magri S, Taroni F, Costa C, Labate A, Gambardella A, Solazzi R, Binda A,  
810 Rivolta I, Di Gennaro G, Casciato S, D’Incerti L, Barbuti A, DiFrancesco D, Granata T,  
811 Gellera C. 2019. HCN ion channels and accessory proteins in epilepsy: genetic analysis of a  
812 large cohort of patients and review of the literature. *Epilepsy Res* **153**:49–58.  
813 doi:10.1016/j.epilepsyres.2019.04.004
- 814 Duhme N, Schweizer PA, Thomas D, Becker R, Schröter J, Barends TRM, Schlichting I, Draguhn  
815 A, Bruehl C, Katus HA, Koenen M. 2013. Altered HCN4 channel C-linker interaction is  
816 associated with familial tachycardia-bradycardia syndrome and atrial fibrillation. *Eur Heart*  
817 *J* **34**:2768–2775. doi:10.1093/eurheartj/ehs391
- 818 Fabbri A, Fantini M, Wilders R, Severi S. 2017. Computational analysis of the human sinus node  
819 action potential: model development and effects of mutations. *J Physiol* **595**:2365–2396.  
820 doi:10.1113/JP273259
- 821 He J-T, Li X-Y, Zhao X, Liu X. 2019. Hyperpolarization-activated and cyclic nucleotide-gated  
822 channel proteins as emerging new targets in neuropathic pain. *Rev Neurosci* **30**:639–649.  
823 doi:10.1515/revneuro-2018-0094
- 824 Hennis K, Biel M, Fenske S, Wahl-Schott C. 2022. Paradigm shift: new concepts for HCN4  
825 function in cardiac pacemaking. *Pflugers Arch* **474**:649–663. doi:10.1007/s00424-022-  
826 02698-4
- 827 Lee C-H, MacKinnon R. 2017. Structures of the Human HCN1 Hyperpolarization-Activated  
828 Channel. *Cell* **168**:111-120.e11. doi:10.1016/j.cell.2016.12.023
- 829 Li N, Artiga E, Kalyanasundaram A, Hansen BJ, Webb A, Pietrzak M, Biesiadecki B, Whitson B,  
830 Mokadam NA, Janssen PML, Hummel JD, Mohler PJ, Dobrzynski H, Fedorov VV. 2021.  
831 Altered microRNA and mRNA profiles during heart failure in the human sinoatrial node.  
832 *Sci Rep* **11**:19328. doi:10.1038/s41598-021-98580-x
- 833 Li N, Csepe TA, Hansen BJ, Dobrzynski H, Higgins RSD, Kilic A, Mohler PJ, Janssen PML, Rosen  
834 MR, Biesiadecki BJ, Fedorov VV. 2015. Molecular Mapping of Sinoatrial Node HCN Channel

- 835 Expression in the Human Heart. *Circ Arrhythm Electrophysiol* **8**:1219–1227.  
836 doi:10.1161/CIRCEP.115.003070
- 837 Macri V, Mahida SN, Zhang ML, Sinner MF, Dolmatova EV, Tucker NR, McLellan M, Shea MA,  
838 Milan DJ, Lunetta KL, Benjamin EJ, Ellinor PT. 2014. A novel trafficking-defective HCN4  
839 mutation is associated with early-onset atrial fibrillation. *Heart Rhythm* **11**:1055–1062.  
840 doi:10.1016/j.hrthm.2014.03.002
- 841 Michels G, Er F, Khan I, Südkamp M, Herzig S, Hoppe UC. 2005. Single-channel properties  
842 support a potential contribution of hyperpolarization-activated cyclic nucleotide-gated  
843 channels and If to cardiac arrhythmias. *Circulation* **111**:399–404.  
844 doi:10.1161/01.CIR.0000153799.65783.3A
- 845 Milanese R, Baruscotti M, Gneocchi-Ruscione T, DiFrancesco D. 2006. Familial sinus bradycardia  
846 associated with a mutation in the cardiac pacemaker channel. *N Engl J Med* **354**:151–157.  
847 doi:10.1056/NEJMoa052475
- 848 Mistrík P, Pfeifer A, Biel M. 2006. The enhancement of HCN channel instantaneous current  
849 facilitated by slow deactivation is regulated by intracellular chloride concentration.  
850 *Pflugers Arch* **452**:718–727. doi:10.1007/s00424-006-0095-0
- 851 Nieto-Marín P, Tinaquero D, Utrilla RG, Cebrián J, González-Guerra A, Crespo-García T, Cámara-  
852 Checa A, Rubio-Alarcón M, Dago M, Alfayate S, Filgueiras-Rama D, Peinado R, López-  
853 Sendón JL, Jalife J, Tamargo J, Bernal JA, Caballero R, Delpón E, ITACA Consortium  
854 Investigators. 2022. Tbx5 variants disrupt Nav1.5 function differently in patients  
855 diagnosed with Brugada or Long QT Syndrome. *Cardiovasc Res* **118**:1046–1060.  
856 doi:10.1093/cvr/cvab045
- 857 Nof E, Luria D, Brass D, Marek D, Lahat H, Reznik-Wolf H, Pras E, Dascal N, Eldar M, Glikson M.  
858 2007. Point mutation in the HCN4 cardiac ion channel pore affecting synthesis, trafficking,  
859 and functional expression is associated with familial asymptomatic sinus bradycardia.  
860 *Circulation* **116**:463–470. doi:10.1161/CIRCULATIONAHA.107.706887
- 861 Nwazue VC, Paranjape SY, Black BK, Biaggioni I, Diedrich A, Dupont WD, Robertson D, Raj SR.  
862 2014. Postural tachycardia syndrome and inappropriate sinus tachycardia: role of  
863 autonomic modulation and sinus node automaticity. *J Am Heart Assoc* **3**:e000700.  
864 doi:10.1161/JAHA.113.000700
- 865 Olshansky B, Sullivan RM. 2019. Inappropriate sinus tachycardia. *EP Eur* **21**:194–207.  
866 doi:10.1093/europace/euy128
- 867 Pérez-Hernández M, Matamoros M, Alfayate S, Nieto-Marín P, Utrilla RG, Tinaquero D, de  
868 Andrés R, Crespo T, Ponce-Balbuena D, Willis BC, Jiménez-Vazquez EN, Guerrero-Serna G,  
869 da Rocha AM, Campbell K, Herron TJ, Díez-Guerra FJ, Tamargo J, Jalife J, Caballero R,  
870 Delpón E. 2018. Brugada syndrome trafficking-defective Nav1.5 channels can trap cardiac  
871 Kir2.1/2.2 channels. *JCI Insight* **3**. doi:10.1172/jci.insight.96291
- 872 Peters CH, Myers ME, Juchno J, Haimbaugh C, Bichraoui H, Du Y, Bankston JR, Walker LA,  
873 Proenza C. 2020. Isoform-specific regulation of HCN4 channels by a family of endoplasmic  
874 reticulum proteins. *Proc Natl Acad Sci U S A* **117**:18079–18090.  
875 doi:10.1073/pnas.2006238117
- 876 Porro A, Saponaro A, Gasparri F, Bauer D, Gross C, Pisoni M, Abbandonato G, Hamacher K,  
877 Santoro B, Thiel G, Moroni A. 2019. The HCN domain couples voltage gating and cAMP  
878 response in hyperpolarization-activated cyclic nucleotide-gated channels. *eLife* **8**:e49672.  
879 doi:10.7554/eLife.49672
- 880 Refisch A, Chung H-Y, Komatsuzaki S, Schumann A, Mühleisen TW, Nöthen MM, Hübner CA,  
881 Bär K-J. 2021. A common variation in HCN1 is associated with heart rate variability in  
882 schizophrenia. *Schizophr Res* **229**:73–79. doi:10.1016/j.schres.2020.11.017
- 883 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector  
884 E, Voelkerding K, Rehm HL, ACMG Laboratory Quality Assurance Committee. 2015.  
885 Standards and guidelines for the interpretation of sequence variants: a joint consensus  
886 recommendation of the American College of Medical Genetics and Genomics and the



- 887 Association for Molecular Pathology. *Genet Med Off J Am Coll Med Genet* **17**:405–424.  
888 doi:10.1038/gim.2015.30
- 889 Rivolta I, Binda A, Masi A, DiFrancesco JC. 2020. Cardiac and neuronal HCN channelopathies.  
890 *Pflugers Arch* **472**:931–951. doi:10.1007/s00424-020-02384-3
- 891 Romeo E, Grimaldi N, Sarubbi B, D'Alto M, Santarpia G, Scognamiglio G, Russo MG, Calabrò R.  
892 2011. A pediatric case of cardiomyopathy induced by inappropriate sinus tachycardia:  
893 efficacy of ivabradine. *Pediatr Cardiol* **32**:842–845. doi:10.1007/s00246-011-9964-1
- 894 Schweizer PA, Duhme N, Thomas D, Becker R, Zehelein J, Draguhn A, Bruehl C, Katus HA,  
895 Koenen M. 2010. cAMP sensitivity of HCN pacemaker channels determines basal heart  
896 rate but is not critical for autonomic rate control. *Circ Arrhythm Electrophysiol* **3**:542–552.  
897 doi:10.1161/CIRCEP.110.949768
- 898 Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. 2005. The FoldX web server: an  
899 online force field. *Nucleic Acids Res* **33**:W382–388. doi:10.1093/nar/gki387
- 900 Sheldon RS, Grubb BP, Olshansky B, Shen W-K, Calkins H, Brignole M, Raj SR, Krahn AD, Morillo  
901 CA, Stewart JM, Sutton R, Sandroni P, Friday KJ, Hachul DT, Cohen MI, Lau DH, Mayuga KA,  
902 Moak JP, Sandhu RK, Kanjwal K. 2015a. 2015 heart rhythm society expert consensus  
903 statement on the diagnosis and treatment of postural tachycardia syndrome,  
904 inappropriate sinus tachycardia, and vasovagal syncope. *Heart Rhythm* **12**:e41-63.  
905 doi:10.1016/j.hrthm.2015.03.029
- 906 Sheldon RS, Grubb BP, Olshansky B, Shen W-K, Calkins H, Brignole M, Raj SR, Krahn AD, Morillo  
907 CA, Stewart JM, Sutton R, Sandroni P, Friday KJ, Hachul DT, Cohen MI, Lau DH, Mayuga KA,  
908 Moak JP, Sandhu RK, Kanjwal K. 2015b. 2015 heart rhythm society expert consensus  
909 statement on the diagnosis and treatment of postural tachycardia syndrome,  
910 inappropriate sinus tachycardia, and vasovagal syncope. *Heart Rhythm* **12**:e41-63.  
911 doi:10.1016/j.hrthm.2015.03.029
- 912 Shi W, Wymore R, Yu H, Wu J, Wymore RT, Pan Z, Robinson RB, Dixon JE, McKinnon D, Cohen  
913 IS. 1999. Distribution and prevalence of hyperpolarization-activated cation channel (HCN)  
914 mRNA expression in cardiac tissues. *Circ Res* **85**:e1-6. doi:10.1161/01.res.85.1.e1
- 915 Ueda K, Nakamura K, Hayashi T, Inagaki N, Takahashi M, Arimura T, Morita H, Higashiesato Y,  
916 Hirano Y, Yasunami M, Takishita S, Yamashina A, Ohe T, Sunamori M, Hiraoka M, Kimura  
917 A. 2004. Functional characterization of a trafficking-defective HCN4 mutation, D553N,  
918 associated with cardiac arrhythmia. *J Biol Chem* **279**:27194–27198.  
919 doi:10.1074/jbc.M311953200  
920

- 921 Verkerk AO, van Borren MMGJ, Peters RJG, Broekhuis E, Lam KY, Coronel R, de Bakker JMT,  
922 Tan HL, Wilders R. 2007. Single cells isolated from human sinoatrial node: action  
923 potentials and numerical reconstruction of pacemaker current. *Annu Int Conf IEEE Eng*  
924 *Med Biol Soc* **2007**:904–907. doi:10.1109/IEMBS.2007.4352437
- 925 Verkerk AO, Wilders R. 2015. Pacemaker activity of the human sinoatrial node: an update on  
926 the effects of mutations in HCN4 on the hyperpolarization-activated current. *Int J Mol Sci*  
927 **16**:3071–3094. doi:10.3390/ijms16023071
- 928 Wainger BJ, DeGennaro M, Santoro B, Siegelbaum SA, Tibbs GR. 2001. Molecular mechanism  
929 of cAMP modulation of HCN pacemaker channels. *Nature* **411**:805–810.  
930 doi:10.1038/35081088
- 931 Wang Z-J, Blanco I, Hayoz S, Brelidze TI. 2020. The HCN domain is required for HCN channel  
932 cell-surface expression and couples voltage- and cAMP-dependent gating mechanisms. *J*  
933 *Biol Chem* **295**:8164–8173. doi:10.1074/jbc.RA120.013281
- 934 Winum P-F, Cayla G, Rubini M, Beck L, Messner-Pellenc P. 2009. A case of cardiomyopathy  
935 induced by inappropriate sinus tachycardia and cured by ivabradine. *Pacing Clin*  
936 *Electrophysiol PACE* **32**:942–944. doi:10.1111/j.1540-8159.2009.02414.x
- 937 Yu H, Gall B, Newman M, Hathaway Q, Brundage K, Ammer A, Mathers P, Siderovski D, Hull  
938 RW. 2021. Contribution of HCN1 variant to sinus bradycardia: A case report. *J Arrhythmia*  
939 **37**:1337–1347. doi:10.1002/joa3.12598

**Table 1.** Clinical characteristics of the family members studied.

Patient	Gender	Age at diagnosis (year range)	Symptoms	Heart Rate (bpm)		Functional Class (NYHA)		LVEF (%)		Treatment	
				Baseline	A. T.	Baseline	A. T.	Baseline	A. T.	Ivabradine (mg BID)	Bisoprolol (5 mg BID)
				Mean 24 h	Mean 24 h						
<b>Carriers</b>											
II-1	M	61-65	Yes	95[13]		III	III	23			
III-1	M	36-40	No	100[15]	90[4]*	I	I	45	55	5	+
III-3 (#)	F	31-35	Yes	106[17]	78[5]*	III	I	43	55	5	+
III-7	F	26-30	Yes	101[13]	85[8]*	I-II	I	45	56	5	+
IV-1	F	21-25	No	103[10]	82[19]*	I	I	51	57	7.5	
IV-4	M	11-15	Yes	111[12]	94[12]*	I	I	60	60	7.5	
IV-5	M	6-10	No	122[15]	101[10]*	I	I	64	64	5	
IV-8	F	11-15	No	112[14]	103[14]*	I	I	60	59	7.5	
IV-9	F	6-10	Yes	117[12]	102[12]*	I	I	63	64	7.5	
<b>Non carriers</b>											
II-5	M	56-60		80[15]				55			
III-5	M	41-45		79[13]				56			
III-8	M	41-45		46[14]				56			
III-9	M	41-45		79[11]				55			
IV-2	F	11-15		84[15]				59			
IV-3	M	16-20		75[15]				58			

#: Proband. A.T. : 3 months after initiation of treatment. BID: twice daily. F: female. HR: heart rate. LVEF: left ventricular ejection fraction. M: male. NYHA: New York Heart Association. Mean 24 h HR data are presented as mean[SD]. Student's t-test followed by Pearson correlation tests. \*P<0.05 vs baseline.

**Tables**-source data 1.

**Table 2.** Resting ECG and cardiac structural parameters of all the family members studied.

Patient	ECG parameters												Chamber characterisation			
	Resting Heart Rate (bpm)		P (ms)		PQ (ms)		QRS (ms)		QT (ms)		QTc (ms)		LVEDD (mm)		LVESD (mm)	
	Baseline	A.T.	Baseline	A. T.	Baseline	A. T.	Baseline	A. T.	Baseline	A. T.	Baseline	A. T.	Baseline	A. T.	Baseline	A. T.
<b>CARRIERS</b>																
II-1	117	-	100	-	120	-	96	-	310	-	380	-	53	-	44	-
III-1	106	73	110	120	140	150	90	90	320	360	390	400	55	56	43	39
III-3 (#)	107	77	120	120	200	160	80	90	320	360	390	400	53	52	40	40
III-7	108	83	100	100	160	160	80	100	320	340	390	400	50	53	33	40
IV-1	102	73	100	100	160	160	80	80	340	360	400	400	46	44	36	31
IV-4	119	90	80	100	180	200	80	80	310	340	390	410	49	50	33	34
IV-5	123	100	80	80	140	160	80	90	300	340	380	400	41	40	27	25
IV-8	123	87	80	100	120	140	80	80	300	340	380	420	45	46	31	30
IV-9	114	94	120	120	160	166	90	100	320	340	400	420	41	42	26	27
<b>NON CARRIERS</b>																
II-5	61	-	100	-	140	-	90	-	380	-	380	-	48	-	34	-
III-5	75	-	100	-	180	-	80	-	340	-	380	-	50	-	34	-
III-8	81	-	100	-	160	-	90	-	360	-	400	-	52	-	40	-
III-9	80	-	80	-	140	-	80	-	340	-	410	-	50	-	34	-
IV-2	82	-	80	-	120	-	80	-	360	-	410	-	43	-	30	-
IV-3	53	-	100	-	160	-	90	-	400	-	420	-	50,2	-	34,8	-

A.T.: 3 months after treatment. bpm: beats per minute. ECG: electrocardiogram. F: female. HR: heart rate. LVEDD: left ventricular end-diastolic diameter. LVEF: left ventricular ejection fraction. LVESD: left ventricular end-systolic diameter. QT values were corrected using the Bazett's and Fredericia's formulas in subjects with HR <100 and ≥100 bpm, respectively. Statistical comparison between baseline measurements and data after treatment was analyzed by paired Student t-tests.

Tables-source data 1.

**Table 3.** Summary of all nonsynonymous variants identified in the proband.

Gene	Genotype	Ancestral allele /Variant	dbSNP_ID	MAF	Aminoacid substitution	Transcript	Provean prediction	SIFT Prediction	Polyphen-2 Prediction	Mutation Taster	CADD Score
<i>CXADR</i>	HET	C/G	-	-	L227V	NM_001338.5	Neutral	Tolerated	Benign	<b>Disease causing</b>	13.8
<i>HCN4</i>	HET	G/A	rs1207487211	0.000003982	V240M	NM_005477.3	Neutral	<b>Deleterious</b>	<b>Probably damaging</b>	<b>Disease causing</b>	<b>28.9</b>
<i>LDB3</i>	HET	-	-	-	P441_S448del	NM_007078.2	-	-	-	-	-

CADD= Combined Annotation Dependent Depletion (A score greater of equal 20 indicates that it is predicted to be the 1% most deleterious substitutions that you can do to the human genome); HET= heterozygous; MAF= mean minor allele frequency from all ethnic groups where the variant has been identified as provided in <https://gnomad.broadinstitute.org/>; SIFT= Sorting Intolerant From Tolerant.

**Table 4.** Effects of p.V240M variant on the time- and voltage-dependent properties of macroscopic and unitary HCN4 currents

Whole-cell							
HCN4	$E_{rev}$ (mV)	$V_{h_{act}}$ (mV)	$k_{act}$	$\Delta I_{NS}/I_{SS}$	$\tau_{deact}$ (s)	$I_{HCN4}$ density -160 mV (pA/pF)	$I_{HCN4}$ density -60 mV (pA/pF)
WT	-6.0±1.9	-131.3±2.5	11.5±0.7	0.62±0.07	0.9±0.2	-43.1±4.7	-1.2±0.2
p.V240M	-6.8±2.3	-111.7±2.6*	12.3±0.7	0.79±0.03*	2.1±0.4*	-128.5±21.2*	-8.6±2.6*
WT+p.V240M	-6.5±1.6	-120.1±2.7*#	13.0±1.0	0.68±0.06	1.4±0.2	-72.9±8.3*#	4.3±1.5*#
Single-channel							
HCN4	$\tau_{OPEN}$ (ms)§	$\tau_{CLOSED}$ (ms)§	MOT (ms)	$f_o$ (Hz)	$P_o$	$i_{HCN4}$ -90 mV (pA)	$\gamma$ (pS)
WT	17.3	68.1	36.2±9.8	5.2±1.1	0.11±0.02	-1.6±0.3	16.3±2.7
p.V240M	9.3*	18.6*	17.1±3.5*	13.2±1.0*	0.23±0.03*	-2.9±0.4*	39.8±4.2*

$\Delta I_{NS}/I_{SS}$ = ratio between the instantaneous current ( $I_{INS}$ ) and the steady-state current ( $I_{SS}$ ) generated by the pulse protocol used to determine the deactivation kinetics after 1-s interval at -40 mV between the two test pulses to -120 mV. MOT= mean open time.  $P_o$ = open probability.  $\tau_{OPEN}$  = open time constant yielded by the fit of a monoexponential function to the open time histogram.  $\tau_{CLOSED}$  = closed time constant yielded by the fit of a monoexponential function to the closed time histogram. Each value represents mean±SEM of >5 cells/experiments (biological replicates) from at least 3 different dishes in each group. Statistical comparisons were made by using ANOVA followed by Tukey's test (Whole-cell) or using *t*-test (single-channel). \*P<0.05 vs WT; #P<0.05 vs p.V240M. §These values are obtained by the fit of a monoexponential fit to the curves constructed with the respective mean values

**Table 5.** Characteristics of the AP generated by a mathematical model of the human sinoatrial node action potential

<b>Parameter</b>	<b>WT</b>	<b>p.V240M</b>	<b>WT+p.V240M</b>
<b>Cycle Length (ms)</b>	814	410	555
<b>Frequency (Hz/bpm)</b>	1.23/73.8	2.44/146.3	1.80/108.1
<b>Diastolic depolarization rate (mV/s)</b>	48.1	126.7	76.7
<b>Mean Diastolic Potential (mV)</b>	-58.9	-57.5	-58
<b>Action potential amplitude (mV)</b>	85.3	81.5	84.0
<b>Overshoot (mV)</b>	26.4	24.0	26.0
<b>APD<sub>20</sub> (ms)</b>	98.5	85.0	93.2
<b>APD<sub>50</sub> (ms)</b>	136	122.9	129.6
<b>APD<sub>90</sub> (ms)</b>	161.5	148.7	155.0

APD<sub>20</sub>, APD<sub>50</sub>, APD<sub>90</sub>= action potential duration measured at 20%, 50% and 90% of repolarization; bpm= beats per minute.